Being Alive 1994 Feb 5: 9
Investigators at the Fred Hutchinson Cancer Research Center have
initiated a gene therapy trial, sponsored by Targeted Genetics Corp.
of Seattle. The trial will use genetically modified cells that
specifically recognize and destroy HIV-infected cells for patients
without opportunistic infections and with CD4 counts between 200 and
The treatment involves the removal of cytotoxic lymphocytes (CTLs)
that recognize and kill HIV-infected cells from a patient's blood and
then the expansion of the CTLs to very large numbers in a cell
culture. These HIV-specific CTLs will then be reinfused into the
patient in an attempt to amplify the immune response to HIV and to
prevent or delay the destruction of the patient's immune system.
The study will enroll 15 HIV+ patients. Each will receive a maximum of
four infusions at increasing cell doses of modified CTLs over a period
of two years. The goal of this study is to evaluate the safety and
efficacy of this type of treatment, known as adoptive immunotherapy.
The first patient received the first course of cell infusion last
month, but the study is still open for enrollment. For information,
you can write the study investigators, Drs. Philip Greenberg and
Stanley Riddell, at the Fred Hutchinson Cancer Research Center,
University of Washington, Seattle, WA 98104.